Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Gorenstein
University of Texas Hlth Sci Ctr Houston, Department: Other Basic Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
AM Biotechnologies, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Gorenstein is a majority owner in a company that owns equity in AM Biotechnologies, LLC. The institution purchases aptamer-related reagents and aptamer libraries, and services related to those reagents and libraries, from AM Biotechologies, LLC for use in some of Dr. Gorenstein's research. For this project, the thioaptamer solution SELEX technology used in the project lis licensed to Am Biotechnologies, LLC.
Aptamer mediated targeting of Fanconi Anemia oral cancer initiating cells
Oral cancer is the most common malignancy of the head and neck region and is associated with a poor prognosis due frequent local and distant tumor relapse after treatment. Tumor relapse is caused by the persistence of cancer stem cells also known as tumor initiating cells. These tumor initiating cells are inherently chemoradiation therapy resistant and hence are not eliminated with the current treatments. Our project is aimed at developing a therapeutic modality that can selectively target the tumor initiating cells and deliver siRNA drugs to overcome their therapeutic resistance in order to improve disease free survival and cure rate in patients with oral cancer.
Filed on August 04, 2014.
Tell us what you know about David Gorenstein's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Gorenstein”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Gorenstein | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | AM Biotechnologies, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.